REGENXBIO posted a GAAP loss of $166.183 million for 9M 2021, up 2.6 times from $65.009 million in the previous year. Revenues decreased by 46.1% to $71.692 million from $133.122 million a year earlier.
REGENXBIO posted a GAAP loss of $166.183 million for 9M 2021, up 2.6 times from $65.009 million in the previous year. Revenues decreased by 46.1% to $71.692 million from $133.122 million a year earlier. 
regenxbio.gcs-web.com
English (US) 